US Stock MarketDetailed Quotes
ORGS Orgenesis
- 0.606
- +0.002+0.36%
Trading Sep 13 10:23 ET
28.42MMarket Cap-757P/E (TTM)
0.640High0.600Low32.18KVolume0.630Open0.604Pre Close19.94KTurnover0.12%Turnover RatioLossP/E (Static)46.93MShares1.08052wk High-1.84P/B16.50MFloat Cap0.25052wk Low--Dividend TTM27.25MShs Float16.800Historical High--Div YieldTTM6.58%Amplitude0.250Historical Low0.619Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Orgenesis Stock Forum
Orgenesis Inc: Data Indicate a Potentially Favorable Safety Profile With a Lower Incidence of Cytokine Release Syndrome
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Orgenesis (NASDAQ: ORGS) announced positive results from a real-world study of its CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia. The study showed complete response rates of 82% in adults and 93% in pediatric patients, with low incidence of severe Cytokine Release Syndrome (2% in adults, 6% in pediat...
NEWS
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
Germfree and Orgenesis Inc. announce a strategic partnership to advance cell and gene therapy production. The collaboration aims to reduce production costs, increase accessibility to treatments, and revolutionize the bio-manufacturing industry. Orgenesis will co-market its Octomera platform wit...
Dow Jones· just
No comment yet